From wellness tracking to clinical decision-support
The integration extends Oura’s Cycle Insights 3.0 suite, introduced in May 2024, which added temperature-trend analysis and cycle-phase predictions to the ring. Maven’s platform will surface those and other metrics inside its patient dashboard so providers can spot early changes in sleep quality, heart-rate variability or body temperature that might signal hormonal shifts or recovery needs.
Research on infertility patients shows that up to 80 percent report heightened anxiety during treatment, yet objective sleep and recovery data are rarely part of consultations. By combining continuous biometrics with virtual visits, Maven aims to give patients clearer feedback and help clinicians tailor recommendations on sleep hygiene, exercise and stress management.
Oura already has a track record in reproductive health through its 2022 integration with the FDA-cleared Natural Cycles birth-control app, and earlier this year it launched an AI health assistant that translates ring data into plain-language insights. The Maven partnership is the latest step in moving those insights into direct clinical workflows. “The collaboration combines Oura’s real-time health signals with Maven’s virtual care to deliver proactive, connected support and better outcomes,” the companies said in a joint statement.
Privacy safeguards, membership costs and rollout
Data sharing is strictly opt-in, and both firms state that all transmitted information remains encrypted and compliant with HIPAA and GDPR rules. Patients can stop sharing at any time inside the Maven app. Because Oura Ring data require an active Oura membership (currently about USD 6 per month), Maven members will need both a ring and a subscription to participate.
Maven plans a phased rollout starting summer 2025, initially targeting users in its fertility and maternity programs before expanding to broader women’s health services. The companies say the long-term goal is to build predictive care models that combine biometric trends with self-reported symptoms and clinician notes, shifting women’s health from reactive treatment to preventive, data-driven guidance.
—
